DDAVP induces systemic release of urokinase-type plasminogen activator.
The desamino-d-arginine vasopressin (DDAVP) induced enhancement of endogenous fibrinolysis is generally attributed to the release of tissue-type plasminogen activator (t-PA) from the vessel wall. The observation of concurrent release of urokinase-type plasminogen activator (u-PA), which eventually might cooperate in the enhanced fibrinolytic activity, has not been reported thus far. In a preliminary study in two healthy human volunteers we found a 1.8-fold increase of urokinase-antigen (UK-antigen) and a 1.7-fold increase of plasmin-activatable pro-urokinase (pro-UK) activity to DDAVP intravenously. The plasma-peak levels coincided with the maximal t-PA level. These responses following infusion of DDAVP were subsequently confirmed in a randomized double blind cross-over study in six human volunteers. We conclude that u-PA is released by DDAVP concurrently with t-PA and that it is presumably from the same origin as t-PA i.e. endothelial cells. u-PA and t-PA may therefore cooperate in the enhanced fibrinolytic activity upon DDAVP infusion.
Levi
M
M
Centre for Thrombosis, Hemostasis and Atherosclerosis Research, University of Amsterdam, The Netherlands.
ten Cate
J W
JW
Dooijewaard
G
G
Sturk
A
A
Brommer
E J
EJ
Agnelli
G
G
D003894:Deamino Arginine Vasopressin / Q000494:pharmacology*; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000378:metabolism*; D006801:Humans; D010865:Pilot Projects; D010960:Plasminogen Activators / Q000378:metabolism*; D011897:Random Allocation; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D005343:Fibrinolytic Agents; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D003894:Deamino Arginine Vasopressin